Prophase Labs (PRPH) Price & Analysis

Prophase Labs released its earnings results on Nov 19, 2025. The company reported -$1.6 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.6.

Is Prophase Labs overvalued?

According to Wall Street analysts Prophase Labs’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Prophase Labs pay dividends?

Prophase Labs pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Prophase Labs dividends here

What is Prophase Labs’s EPS estimate?

Prophase Labs’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Prophase Labs have?

Prophase Labs has 5,768,951 shares outstanding.

What happened to Prophase Labs’s price movement after its last earnings report?

Prophase Labs reported an EPS of -$1.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.302%.

Which hedge fund is a major shareholder of Prophase Labs?

Currently, no hedge funds are holding shares in PRPH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Prophase Labs Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-28.44%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Prophase Labs

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Prophase Labs (PRPH) Earnings & Revenues

Historic Earnings Reports

PRPH Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted several promising developments, such as the Crown Medical collections, potential partnerships for the esophageal cancer test, and a turnaround in the Nebula Genomics business. However, these positives were counterbalanced by significant challenges, including financial constraints, a declining stock price, and the need for a reverse stock split to maintain Nasdaq compliance. The company is actively pursuing strategic initiatives to address these issues and improve shareholder value.View all PRPH earnings summaries